Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments ...

This transaction was a mandatory sale to cover tax obligations associated with the vesting of restricted stock units (RSUs), as stipulated by Scholar Rock's equity incentive plans. These RSUs were ...

Scholar Rock has done well to advance its anti-myostatin ... but also to see if this drug is ultimately approved to treat this specific neuromuscular patient population. What I wanted to note ...

The transaction comes as Scholar Rock, now valued at $4.19 billion ... The company is also expanding the use of apitegromab into other rare neuromuscular conditions and advancing its ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...